^
Association details:
| Biomarker: | PD-L1 elevation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) + Imjudo (tremelimumab) (CTLA4 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
433P - Durvalumab and tremelimumab in combination with FOLFOX in patients with previously untreated RAS-mutated metastatic colorectal cancer: First results of efficacy at one year for phase II MEDITREME trial
Published date:
09/13/2021
Excerpt:
The aim of single arm phase II MEDITREME trial was to evaluate efficacy and safety of mFOLFOX6 (6 cycles) in combination with durvalumab (750mg/q2W) and tremelimumab (75mg/q4W) as induction therapy followed by maintenance therapy with durvalumab in patients with previously untreated RAS-mutated MCRC....High baseline levels of Th2 and PDL1+ MDSC were associated with poor PFS.
Secondary therapy:
Modified FOLFOX6
